(Q37880078)

24 August 2017

1 reference

title

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles (English)

1 reference

24 August 2017

1 reference

3

Ray Borrow

1 reference

24 August 2017

Xilian Bai

1

1 reference

PubMed ID

21615224

24 August 2017

Jamie Findlow

series ordinal

2

1 reference

PubMed ID

21615224

24 August 2017

language of work or name

English

0 references

publication date

26 May 2011

1 reference

Expert Opinion on Biological Therapy

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

7

1 reference

24 August 2017

969-985

1 reference

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Global epidemiology of meningococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Meningococcal surrogates of protection--serum bactericidal antibody activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

NadA, a novel vaccine candidate of Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

NadA diversity and carriage in Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Chemokine patterns in meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16???24 Months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.585965

10.1517/14712598.2011.585965

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21615224